Mechanism of action
Ritonavir has a dual mechanism of action. As an HIV-1 protease inhibitor, it binds to the active site of the viral protease enzyme, preventing cleavage of the Gag-Pol polyprotein precursor. This inhibition results in the production of immature, non-infectious viral particles.
However, ritonavir's primary clinical role exploits its potent inhibition of cytochrome P450 3A4 (CYP3A4) and, to a lesser extent, CYP2D6. When co-administered with other protease inhibitors or antiretrovirals, ritonavir dramatically reduces their hepatic metabolism, increasing their plasma concentrations and extending their half-lives. This pharmacokinetic boosting allows for lower doses, less frequent dosing, and improved efficacy of the primary antiretroviral agent.
At boosting doses (typically 100-200 mg), ritonavir provides minimal direct antiviral activity but maximizes the pharmacokinetic enhancement. This CYP3A4 inhibition is irreversible, requiring synthesis of new enzymes, which can take several days after discontinuation.
- Ritonavir's primary clinical use is as a CYP3A4 inhibitor to boost levels of other protease inhibitors, not for direct antiviral effect at low doses.
- Potent CYP3A4 inhibition causes extensive drug interactions; contraindicated with simvastatin, lovastatin, midazolam, ergots, and many antiarrhythmics.
- Common adverse effects include gastrointestinal disturbances (nausea, diarrhea), dyslipidemia, and hyperglycemia.
- Ritonavir significantly increases triglycerides and cholesterol; lipid-lowering therapy often required with statin dose adjustments.
- Used in fixed-dose combination with lopinavir (Kaletra) and to boost atazanavir, darunavir, and other protease inhibitors.
- Rifampin is contraindicated due to potent CYP3A4 induction that reduces ritonavir levels; rifabutin requires dose reduction.
- Ritonavir is both a CYP3A4 substrate and inhibitor, leading to auto-inhibition and complex pharmacokinetics.
- No renal dose adjustment needed, but use with caution in hepatic impairment; contraindicated in decompensated cirrhosis.
Indications
The primary indication for ritonavir is as a pharmacokinetic booster in combination antiretroviral therapy for HIV-1 infection. It is used to enhance the pharmacokinetics of:
- Protease inhibitors: lopinavir, atazanavir, darunavir, tipranavir
- Other antiretrovirals: elvitegravir
Ritonavir is available as a single agent but is more commonly used in fixed-dose combinations, most notably lopinavir/ritonavir. It is not used as monotherapy due to rapid resistance development and poor tolerability at full antiviral doses.
Ritonavir-boosted regimens are used in treatment-naïve and treatment-experienced patients, including those with resistant virus. The choice of boosted protease inhibitor depends on resistance patterns, tolerability, and drug interaction considerations.
Pharmacokinetics
Absorption: Ritonavir is administered orally and is well absorbed, with bioavailability increased when taken with food. Peak plasma concentrations occur approximately 2-4 hours after administration.
Distribution: Ritonavir is highly protein-bound (98-99%), primarily to albumin and alpha-1-acid glycoprotein. It has poor central nervous system penetration.
Metabolism: Ritonavir is extensively metabolized in the liver by CYP3A4 and CYP2D6. It is both a substrate and a potent inhibitor of CYP3A4, leading to auto-inhibition and complex pharmacokinetic interactions. Ritonavir also inhibits P-glycoprotein, further affecting drug disposition.
Elimination: The elimination half-life is 3-5 hours. Metabolites are primarily excreted in feces (86%), with minimal renal excretion (11%). No dose adjustment is required for renal impairment, but caution is advised in hepatic impairment.
Ritonavir induces its own metabolism with repeated dosing, but the net effect is still profound CYP3A4 inhibition when used as a booster.
Adverse effects
Ritonavir is associated with significant adverse effects, particularly at higher doses. When used as a pharmacokinetic booster, tolerability is generally improved but side effects remain common.
Gastrointestinal effects
- Nausea, vomiting, diarrhea (very common, dose-limiting)
- Abdominal pain
- Dysgeusia (altered taste)
Metabolic effects
- Dyslipidemia: marked elevation of total cholesterol, LDL, and triglycerides
- Hyperglycemia and insulin resistance
- Lipodystrophy (fat redistribution syndrome)
Hepatotoxicity
- Transaminase elevations
- Hepatitis (particularly in patients with hepatitis B or C co-infection)
Other effects
- Asthenia, headache
- Paresthesias (circumoral and peripheral)
- QT and PR interval prolongation (less common than with other protease inhibitors)
- Increased bleeding in hemophiliacs
- Immune reconstitution inflammatory syndrome (IRIS)
Laboratory abnormalities
- Elevated liver enzymes
- Elevated creatine kinase
- Hyperuricemia
Gastrointestinal side effects often improve with continued use or dose escalation strategies.
Contraindications and warnings
Contraindications
Ritonavir is contraindicated with drugs that are highly dependent on CYP3A4 metabolism and for which elevated concentrations could cause serious or life-threatening adverse events. These include:
- Antiarrhythmics: amiodarone, flecainide, propafenone, quinidine
- Ergot derivatives: dihydroergotamine, ergotamine, methylergonovine
- Sedatives/hypnotics: midazolam (oral), triazolam, pimozide
- PDE5 inhibitors: sildenafil (for pulmonary hypertension)
- HMG-CoA reductase inhibitors: lovastatin, simvastatin
- Alfuzosin, ranolazine, dronedarone
- Colchicine in patients with renal or hepatic impairment
Warnings and precautions
- Hepatic impairment: use with caution; contraindicated in decompensated cirrhosis
- Hemophilia: increased bleeding risk
- Diabetes: may exacerbate hyperglycemia or precipitate diabetes
- Pancreatitis: risk increased, particularly with hypertriglyceridemia
- PR interval prolongation: caution in patients with cardiac conduction abnormalities
- Pregnancy: pregnancy category B; generally considered safe but may require dose adjustments
Regular monitoring of lipids, glucose, and liver function is recommended during therapy.
Drug interactions
Ritonavir has extensive drug interactions due to its potent CYP3A4 inhibition. It can increase concentrations of co-administered drugs metabolized by this pathway, leading to toxicity, or be affected by CYP3A4 inducers that reduce its efficacy.
Major interactions requiring dose adjustment or avoidance
- Statins: avoid lovastatin and simvastatin; use atorvastatin, rosuvastatin, or pravastatin with dose reduction
- Calcium channel blockers: reduce doses of amlodipine, diltiazem, nifedipine
- Immunosuppressants: significantly increases cyclosporine, tacrolimus, sirolimus levels; close monitoring required
- Anticoagulants: warfarin levels may be altered; monitor INR closely; rivaroxaban and apixaban require dose reduction
- Corticosteroids: increases fluticasone and budesonide; may cause Cushing syndrome; avoid or use alternatives
- Antifungals: bidirectional interaction with ketoconazole, itraconazole; dose adjustments needed
- Rifamycins: rifampin significantly reduces ritonavir levels and is contraindicated; rifabutin requires dose reduction
Other antiretrovirals
- Boosting effect is exploited with atazanavir, darunavir, lopinavir
- May interact with non-nucleoside reverse transcriptase inhibitors; some combinations require adjustments
Drugs that reduce ritonavir efficacy
- CYP3A4 inducers: phenytoin, carbamazepine, phenobarbital, St. John's wort (contraindicated)
A complete drug interaction review is essential before initiating ritonavir due to the extensive list of affected medications.
Clinical pearls
- Ritonavir is rarely used for its antiviral properties at full doses (600 mg twice daily) due to poor tolerability; modern use is almost exclusively as a 100-200 mg booster.
- Cobicistat is an alternative pharmacokinetic booster that inhibits CYP3A4 without antiviral activity; it may have fewer gastrointestinal side effects but similar drug interaction profiles.
- The "bitter taste" of ritonavir is a classic complaint; liquid formulations are particularly poorly tolerated due to taste and ethanol content.
- Lipid monitoring is essential: ritonavir-containing regimens often require lipid-lowering therapy. Use pravastatin, rosuvastatin, or low-dose atorvastatin; never lovastatin or simvastatin.
- Drug interaction checks are mandatory before prescribing any new medication to a patient on ritonavir. Many interactions are bidirectional and complex.
- Ritonavir boosting improves adherence by allowing once-daily dosing of some protease inhibitors and reducing pill burden in fixed-dose combinations.
- Hypersensitivity reactions (including Stevens-Johnson syndrome) are rare but have been reported; discontinue if rash with systemic symptoms occurs.
- Food increases absorption: ritonavir should be taken with food to improve tolerability and bioavailability.
- Gradual dose escalation can improve gastrointestinal tolerability when initiating therapy, though this is less relevant at boosting doses.
- In resource-limited settings, ritonavir-boosted protease inhibitor regimens are important second-line options after first-line non-nucleoside reverse transcriptase inhibitor or integrase inhibitor failure.
Practice questions
1. A 42-year-old man with HIV infection is started on a ritonavir-boosted protease inhibitor regimen. Four weeks later, he develops muscle pain and dark urine. Laboratory studies show creatine kinase 8,500 U/L (normal <200) and elevated transaminases. He reports no recent trauma or excessive exercise. Which medication is most likely responsible for this presentation?
2. A 35-year-old woman with HIV on lopinavir/ritonavir presents with progressive central obesity, dorsocervical fat pad enlargement, and facial rounding over 6 months. She also reports easy bruising and purple striae on her abdomen. She has been using inhaled fluticasone for asthma. Laboratory studies show elevated morning cortisol and suppressed ACTH. What is the most appropriate next step?
3. A 50-year-old man with HIV is being treated with darunavir/ritonavir, tenofovir, and emtricitabine. He develops tuberculosis and is started on rifampin-based therapy by the infectious disease team. Two weeks later, his HIV viral load increases from undetectable to 50,000 copies/mL. What is the most likely explanation?
Frequently asked questions
How does ritonavir work?
Ritonavir works by inhibiting HIV-1 protease, preventing viral maturation, and by potently inhibiting cytochrome P450 3A4 (CYP3A4). At the low doses used clinically, its primary function is as a pharmacokinetic booster: it increases the plasma concentrations and prolongs the half-lives of co-administered protease inhibitors and other antiretrovirals by blocking their hepatic metabolism. This allows for more effective HIV treatment with fewer pills and less frequent dosing.
What are the side effects of ritonavir?
The most common side effects of ritonavir are gastrointestinal (nausea, diarrhea, vomiting, abdominal pain) and altered taste. Metabolic side effects include significant dyslipidemia with elevated cholesterol and triglycerides, hyperglycemia, insulin resistance, and lipodystrophy. Hepatotoxicity with elevated liver enzymes can occur, particularly in patients with hepatitis B or C. Other effects include headache, asthenia, paresthesias, and rarely, PR or QT interval prolongation. Many side effects are dose-related and less severe at the low boosting doses.
Is ritonavir a controlled substance?
No, ritonavir is not a controlled substance. It is a prescription antiretroviral medication used in the treatment of HIV infection and does not have abuse potential. However, it requires careful prescribing due to extensive drug interactions and the need for combination antiretroviral therapy to prevent resistance development.
What drugs should not be taken with ritonavir?
Ritonavir is contraindicated with many drugs metabolized by CYP3A4 where increased levels could be dangerous. These include simvastatin and lovastatin (use alternative statins), oral midazolam and triazolam (sedatives), ergot derivatives, certain antiarrhythmics (amiodarone, flecainide, quinidine), pimozide, alfuzosin, sildenafil for pulmonary hypertension, and St. John's wort. Rifampin is also contraindicated as it reduces ritonavir efficacy. Many other drugs require dose adjustments. Always check for interactions before prescribing any new medication to a patient taking ritonavir.
Ritonavir vs cobicistat — what is the difference?
Both ritonavir and cobicistat are pharmacokinetic boosters that inhibit CYP3A4 to increase levels of other antiretrovirals. The key difference is that ritonavir is also an HIV protease inhibitor with antiviral activity, while cobicistat has no antiviral effect and functions purely as a booster. Cobicistat may have fewer gastrointestinal side effects and does not contain the ethanol found in ritonavir liquid formulations, but both have extensive and similar drug interaction profiles. Ritonavir has a longer history of use and is available in more fixed-dose combinations.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: J05AE03
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.